Published in Clin Exp Pharmacol Physiol on June 11, 2004
Feasibility of tissue plasminogen activator formulated for pulmonary delivery. Pharm Res (2005) 0.90
Accelerated dosing frequency of a pulmonary formulation of tissue plasminogen activator is well-tolerated in mice. Clin Exp Pharmacol Physiol (2008) 0.87
Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in mice. Pulm Pharmacol Ther (2009) 0.86
Proteolytic regulation of epithelial sodium channels by urokinase plasminogen activator: cutting edge and cleavage sites. J Biol Chem (2015) 0.79
Tissue plasminogen activator attenuates ventilator-induced lung injury in rats. Acta Pharmacol Sin (2012) 0.76
NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol (2004) 2.18
A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res (2007) 1.89
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs (2006) 1.63
Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol (2005) 1.47
Autophagy and cancer therapy. Mol Pharmacol (2014) 1.38
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol (2009) 1.30
Long-term effects of a trophic cascade in a large lake ecosystem. Proc Natl Acad Sci U S A (2011) 1.22
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res (2006) 1.19
STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res (2014) 1.17
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res (2007) 1.09
In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: effects on biodistribution and tumor accumulation. J Pharm Sci (2008) 1.08
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol (2007) 1.01
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res (2013) 1.01
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2010) 0.98
Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. Cancer Chemother Pharmacol (2010) 0.96
Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One (2013) 0.95
Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues. J Pharm Biomed Anal (2005) 0.89
Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma. Am J Vet Res (2006) 0.87
Accelerated dosing frequency of a pulmonary formulation of tissue plasminogen activator is well-tolerated in mice. Clin Exp Pharmacol Physiol (2008) 0.87
Optimizing preclinical study design in oncology research. Chem Biol Interact (2011) 0.87
Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity. Int Immunopharmacol (2012) 0.85
Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation. Clin Cancer Res (2010) 0.85
Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans. J Pharmacokinet Pharmacodyn (2013) 0.84
Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas. Am J Vet Res (2012) 0.84
Inhibition of human neutrophil reactive oxygen species production and p67phox translocation by cigarette smoke extract. Atherosclerosis (2005) 0.84
Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson's disease. J Pharmacol Exp Ther (2013) 0.82
Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. Clin Cancer Res (2010) 0.82
Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. Front Pharmacol (2013) 0.81
Particulate phase cigarette smoke increases MnSOD, NQO1, and CINC-1 in rat lungs. Free Radic Biol Med (2004) 0.80
Structure-activity relationships for biodistribution, pharmacokinetics, and excretion of atomically precise nanoclusters in a murine model. Nanoscale (2013) 0.79
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol (2008) 0.79
Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice. J Pharmacokinet Pharmacodyn (2013) 0.79
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin Cancer Res (2004) 0.79
Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. Mol Cancer Ther (2008) 0.78
Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere. Cancer Chemother Pharmacol (2015) 0.78
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Mol Cancer Ther (2008) 0.78
A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther (2013) 0.77
Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay. Toxicol Sci (2003) 0.77
Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. Am J Vet Res (2016) 0.77
Customized in silico population mimics actual population in docetaxel population pharmacokinetic analysis. J Pharm Sci (2010) 0.77
Quantification of stem-cement interfacial gaps: in vitro CT analysis of Charnley-Kerboul and Lubinus SPII femoral hip implants. J Bone Joint Surg Br (2008) 0.77
Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice. Anticancer Drugs (2013) 0.76
Development of a rapid multiplexed assay for the direct screening of antimicrobial residues in raw milk. Anal Bioanal Chem (2015) 0.76
Rapid and sensitive LC-MS/MS method for determination of felbamate in mouse plasma and tissues and human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.75
Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor. BMC Vet Res (2014) 0.75
Pharmacokinetics and safety of silibinin in horses. Am J Vet Res (2013) 0.75
Evaluation of antioxidant capacity and inflammatory cytokine gene expression in horses fed silibinin complexed with phospholipid. Am J Vet Res (2013) 0.75
Field-based evaluation of biopesticide impacts on native biodiversity: malagasy coleoptera and anti-locust entomopathogenic fungi. J Econ Entomol (2002) 0.75
Evaluation of the ocular penetration of topical alpha-luminol (Galavit®/GVT®). Vet Ophthalmol (2011) 0.75
Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus). Am J Vet Res (2015) 0.75
Alterations of drug metabolism in critically ill animals. Vet Clin North Am Small Anim Pract (2011) 0.75
Pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in cats after oral, intravenous, and intraperitoneal administration of cyclophosphamide. Am J Vet Res (2017) 0.75
Population pharmacokinetic model of PI-88, a heparanase inhibitor. Cancer Chemother Pharmacol (2009) 0.75